BioNano Genomics Inc vs VanEck Semiconductor ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while VanEck Semiconductor ETF trades at $584.97. The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SMH | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | — |
52-Week High | $4.92 | $668.91 |
52-Week Low | $1.09 | $283.95 |
Enterprise Value | $15.81M | — |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
SMH (VanEck Semiconductor ETF) trades at $585.62, down 4.22% over 24 hours amid a sector-wide sell-off. Technical indicators show a bearish trend with support at $579 and resistance at $589. Recent news highlights strong 2026 performance but notes high expectations and recent volatility in semiconductor stocks.
The ETF's outlook is clouded by near-term volatility, though long-term AI-driven demand for semiconductors remains a tailwind. Risks include sector concentration and macroeconomic pressures, but diversification within the chip industry offers a balanced exposure for investors seeking growth in technology infrastructure.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →